Skip to main content
AMGN logo

Amgen Inc. (AMGN) Stock: Price, Forecast & Analyst Target

Amgen Inc. (AMGN) — MoonshotScore 84/100 (Exceptional band), calculated Nov 18, 2026. Price $443.89 (-3.07%), as of the Nov 18, 2026 trading session; market cap $240B. Expected results Feb 2, 2027.

Educational signal · not a buy or sell recommendation · How to read this

$443.89 −$14.04 (-3.07%) Market Cap $240B

Amgen Inc. · AMGN · NASDAQ · Healthcare · Drug Manufacturers - General

Research dated 2026-09-12: Amgen is a commercial biotechnology company whose medicines span inflammation, bone health, cardiovascular disease, oncology, hematology, nephrology and neuroscience. The case hinges on whether portfolio growth and cash generation can support heavy debt and the manufacturing build for MariTide without eroding the economics of the established franchise.

Price as of Nov 18, 2026

Key Statistics

84 of 100

MoonshotScore v2 · Amgen (AMGN)

Exceptional
Business Quality Elite (93)
Financial Safety Okay (49)
Valuation Full (44)
Growth Durability Growing (67)
Momentum Surging (90)
Why this rating? Method, drivers & history

Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.

  • Business Quality — Is this a genuinely good business?
  • Financial Safety — Could this blow up on me?
  • Valuation — Am I paying a fair price?
  • Growth Durability — Is the growth real and likely to last?
  • Momentum — Is the market already moving on this?
The ten-second read ·

Elite quality, but a full valuation; the market is already moving on it. Business Quality: Elite; Financial Safety: Okay; Valuation: Full; Growth Durability: Growing; Momentum: Surging.

  • EPS beat 0 of the last 4 reports
  • expected results Feb 2, 2027
  • Altman Z 2.55 · Piotroski F 8

Helping: business quality, positive momentum

What has the MoonshotScore done over time?

MoonshotScore snapshots recorded for AMGN (57 recorded, newest six shown)
RecordedScoreBand
86Exceptional
84Exceptional
86Exceptional
86Exceptional
84Exceptional
84Exceptional

Daily score refresh is delayed. This is the last recorded calculation.

Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.

Computed · How the MoonshotScore is computed →

Price & valuation

Dates shown where recorded
MeasureValueAs of
Latest provided price$443.89
Change on the day-3.07%
52-week range$312.39–$483.99
Market capitalisation$240B—
Price / earnings (trailing)26.35
Shares traded on the day2.58M
Beta (volatility vs the S&P 500)0.42

Why Amgen scores 84

Dr. Mira Sol, the Stock Expert AI TV data character
Business Quality carries the score; Valuation is what holds it back.
Dr. Mira Sol · Data scientist, Stock Expert AI TV (fictional AI character)
84Exceptional
  • Business Quality93
  • Financial Safety49
  • Valuation44
  • Growth Durability67
  • Momentum90

Share price, last 12 months +43.7%

$323.66 $465.23

What the price assumes

10.8% a year of free-cash-flow growth for ten years is what a $251.52B market value ( snapshot) asks for.

  • Price implies, next ten years10.8%
  • Free cash flow, last 5 years-3.9%
  • Revenue, last 5 years7.6%
  • Analysts' revenue path, 2026–20304.4%

The price already assumes faster growth than the last 5 years delivered. Anything short of an acceleration leaves room to disappoint. It also runs ahead of the analysts' revenue path.

Reverse discounted cash flow: 10% discount rate, 3% growth after year ten, starting from trailing twelve months free cash flow of $9.58B. Inputs: FMP statements, estimates and quote.

How the stock reacts to earnings

EPS beat in 11 of the last 12 reports (2024–2026); the stock still fell the next session after 4 of those beats. Average first-session move: 5.7% either way.

  1. -8.1%Feb ’24
  2. +12.2%May ’24
  3. -3.9%Aug ’24
  4. +1.3%Oct ’24
  5. +6.6%Feb ’25
  6. -3.3%May ’25
  7. -5.7%Aug ’25
  8. +8.0%Nov ’25
  9. +6.2%Feb ’26
  10. -2.4%Apr ’26
  11. +7.6%Aug ’26
  12. +2.8%Nov ’26
Next-session move EPS beat (11) EPS in line (1)
Every report, with revenue and five-session moves
Moves run from the close before the report to the first and fifth closes after it.
ReportEPSRevenueNext session5 sessions
BeatBeat+2.8%—
BeatBeat+7.6%+9.4%
BeatIn line-2.4%-2.6%
BeatBeat+6.2%+5.8%
BeatBeat+8.0%+14.2%
BeatBeat-5.7%-5.6%
BeatBeat-3.3%-6.5%
BeatBeat+6.6%+2.7%
BeatIn line+1.3%+1.8%
In lineIn line-3.9%-0.5%
BeatIn line+12.2%+12.8%
BeatIn line-8.1%-9.8%

Beats have usually been rewarded — 7 of 11 drew a higher close the next session.

What management is saying differently

Management's own words on the Q3 FY2026 call () against Q2 FY2026 (). Analysts' questions are left out.

  • New this call: “cornerstone therapy”, “cytokine release”, “first-line maintenance”, “frontline maintenance” — none of them came up in Q2 FY2026.
  • Getting louder: “small cell” (6 → 12 mentions), “overall survival” (2 → 6 mentions), “serious diseases” (1 → 5 mentions).
  • Gone quiet: “cardiovascular disease”, “iii clinical”, “care physicians”, “essdai score” — regular themes last call, absent this time.
  • Tone: Cautious words such as “may”, “could” and “headwind” fell from 3 to 2.2 per 1,000 words, and confident words such as “record” and “strong” rose from 5 to 5.1.

Management sounded more assured than a quarter earlier — fewer hedging words, more of the confident kind.

Our track record on this stock

Since the score went from 85 to 84 while the share price moved +0.0% through .

MoonshotScore (0–100, band floors 45 · 65 · 80) Share price, scaled to its own range

The score has stayed in the Exceptional band across the stretch we have recorded; we grade each band change three months after it happens.

The crowd against our signals

  • Analysts: 51% of 41 rate it a buy; the average target sits -6.4% from the price of $443.89.
  • Last 90 days: 0 upgrades and 3 downgrades among 37 rating actions.
  • Our signals: Exceptional band; strongest pillar Business Quality (93), weakest Valuation (44).

Our signals are more constructive than the crowd, led by Business Quality.

Price & events

Weekly closing price with reported quarters marked Weekly closing price from Oct 17, 2025 to Nov 18, 2026: low $292, high $466, latest $444. 4 reported quarters marked, 4 above and 0 below the recorded estimate. $466 $292 high $466 Feb 3, 2026 · Earnings results · reported above the recorded estimate · close $3841Apr 30, 2026 · Earnings results · reported above the recorded estimate · close $3302Aug 4, 2026 · Earnings results · reported above the recorded estimate · close $4113Nov 3, 2026 · Earnings results · reported above the recorded estimate · close $4604 Oct 17, 2025 Nov 18, 2026 · $444 $299Oct 17, 2025$298Oct 31, 2025$337Nov 14, 2025$345Nov 28, 2025$318Dec 12, 2025$333Dec 26, 2025$326Jan 9, 2026$345Jan 23, 2026$384Feb 6, 2026$375Feb 20, 2026$370Mar 6, 2026$348Mar 20, 2026$348Apr 2, 2026$355Apr 17, 2026$330May 1, 2026$326May 15, 2026$337May 29, 2026$355Jun 12, 2026$358Jun 26, 2026$363Jul 10, 2026$376Jul 24, 2026$411Aug 7, 2026$439Aug 21, 2026$437Sep 4, 2026$386Sep 18, 2026$403Oct 2, 2026$432Oct 16, 2026$466Oct 30, 2026$466Nov 13, 2026

Triangles mark reported quarters on the line: pointing up is above the recorded estimate, down is below, a diamond means no estimate on file. Numbers key to the dated list. Point at or tab to any week for its close.

Events behind the price

  • · Earnings results · above the recorded estimate
  • · Earnings results · above the recorded estimate
  • · Earnings results · above the recorded estimate
  • · Earnings results · above the recorded estimate

Results dates follow the earnings feed; call dates follow the transcript provider. Nearby dates do not establish that an event caused a price move.

Upcoming events

As of

  1. Next results dueProvider estimate
How to read these dates

Estimated dates can change.

What to watch next

Other perspectives

Council score for Amgen (AMGN): perspectives

Some lenses disagree with the MoonshotScore. Compare their readings below; each uses a different method.

5-Factor Breakdown

Business Quality Strong
Financial Safety Neutral
Valuation Neutral
Growth Durability Moderate
Momentum Strong

Legends Council

3 lenses, 3 current

AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built

Englander-style lens (simulated) Izzy Englander Neutral read
Klarman-style lens (simulated) Seth Klarman Neutral read
Moon AI lens (model) Favorable read

Read on: Nov 20, 2026

Munger's Mindset

Balance Sheet & Valuation

Financial Health Neutral
Margin of Safety Overvalued
Profit Margin Strong
Revenue Growth Neutral
Debt/Equity Negative
ROE Strong
Gross Margin Strong

Read on: Nov 19, 2026

How to read these bars and different assessments

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.

One of these lenses reads this company less favourably than the MoonshotScore does: Munger lens (margin of safety). Each lens is a separate scoring function over its own inputs, so a disagreement is a difference of method rather than a correction — the page's answer stays the MoonshotScore above.

The Munger lens reads the current price as overvalued against its own estimate of value.

Readings on this page are from Nov 20, 2026, except a card that shows its own read date.

1 · What is it?

What is Amgen (AMGN), and what does it report?

Short answer · as of

Amgen develops, manufactures and sells prescription medicines used in specialist care, including Prolia, Repatha, Enbrel and Otezla.

Demand ultimately comes from treated patients and prescribing decisions, while physicians, clinics, dialysis centers, hospitals and pharmacies form the commercial channel, supported by wholesale distribution.

The reported revenue line combines products with very different indications and demand patterns, so Amgen is not economically equivalent to a biotechnology company awaiting its inaugural commercial therapy. Its accounts measure an established medicine portfolio alongside substantial research, selling and administrative spending.

2 · Latest results

What do the latest results show for Amgen (AMGN)?

The latest period delivered a marked rise in revenue, gross profit, operating profit, net income and diluted earnings from the preceding period. Revenue and earnings also cleared market estimates, extending a consistent run of results above consensus.

The financial series establishes the improvement; management’s explanation is forward-looking. Planned manufacturing investment is intended to accommodate volume growth and prepare capacity for MariTide, while the stated outlook calls for continued revenue growth and strong operating profitability.

Where is operating spending going?

Revenue alongside research and development, selling, general and administrative expenses, and the FMP standardized operating result.

Period endRevenueR&DSG&AFMP standardized operating result
Sep 30, 2026Not availableNot availableNot availableNot available
Jun 30, 2026Not availableNot availableNot availableNot available
Mar 31, 2026Not availableNot availableNot availableNot available
Dec 31, 2025Not availableNot availableNot availableNot available
How to read these figures

Amounts are in US dollars. The operating result is Financial Modeling Prep’s standardized figure, so it can differ from the operating line in the company’s filing. It is not net income or cash flow.

Did results meet expectations?

Reported earnings and revenue alongside the estimates recorded by the provider.

Latest report · revenue
$10.37B Nov 3, 2026
Latest report · revenue estimate
$10.07B Nov 3, 2026
Latest report · revenue vs estimate
Above estimate Nov 3, 2026
Latest report · EPS vs estimate
Above estimate Nov 3, 2026
Report dateRevenue · reportedRevenue · estimateEPS · reportedEPS · estimate
Nov 3, 2026$10.37B$10.07B$6.4500$5.7900
Aug 4, 2026$10.05B$9.43B$6.2900$5.6200
Apr 30, 2026$8.62B$8.58B$5.1500$4.7700
Feb 3, 2026$9.87B$9.47B$5.2900$4.7300
How to read these figures

Dates are when results were reported, not quarter ends. Amounts are in US dollars; EPS is per share. The source does not say whether EPS is basic, diluted or adjusted, so it can differ from the EPS in the income statement.

Quarterly income statement — 4 quarters
Revenue, net income and earnings per share by quarter
PeriodRevenueNet incomeEPS
Sep 2025$9.56B$3.22B$5.93 (diluted)
Q4 FY2025$9.87B$1.33B$2.45 (diluted)
Q1 FY2026$8.62B$1.82B$3.34 (diluted)
Q2 FY2026$10.05B$2.38B$4.37 (diluted)
3 · Financial strengths and risks

What are the financial strengths and risks for Amgen (AMGN)?

Short answer

Cash and short-term investments were $0.00 at the Sep 30, 2026 balance-sheet date. This figure does not establish a cash runway.

Amgen pairs high gross and operating margins with substantial operating cash generation. Cash and short-term investments have risen sharply from the recent low, and the latest operating cash inflow comfortably exceeded capital expenditure.

Debt nevertheless stands far above available cash, while leverage remains elevated. That makes sustained product cash flow especially important: weaker operating performance combined with the MariTide capacity program would reduce room for debt reduction or other capital uses. Revenue has expanded across the annual series, but net income has been much less orderly, reinforcing the distinction between commercial growth and earnings stability.

4 · What to check next?

What should you watch next at Amgen (AMGN)?

Short answer · as of

The next earnings report is expected on Feb 2, 2027.

MariTide spending is the most concrete operational checkpoint. Watch whether capital expenditure rises as planned, whether operating cash flow continues to cover that build comfortably, and whether management preserves its product-sales margin outlook while adding capacity.

The next earnings release also tests whether revenue can remain near the latest elevated level and whether Amgen can extend its run of results above expectations. Longer-range analyst estimates embed continued revenue and earnings expansion, so any widening gap between portfolio growth, cash conversion and consensus expectations would matter.

What the records here don't tell us

  • No forward revenue or earnings estimate is on file.

Checked against the records this page reads, on the dates shown above.

5 · Peer comparison

How does Amgen compare with its peers?

Short answer

Amgen's score ranks 5th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.

Amgen differs from development-stage biotechnology businesses because it already manufactures and distributes a broad portfolio of widely used medicines through established healthcare channels. Its results therefore depend on aggregate prescribing and patient demand across marketed franchises, not solely on a clinical milestone.

The biotechnology character remains visible in heavy research spending and the need to fund manufacturing before prospective demand arrives. This combination of mature commercial cash flow, continued scientific investment and meaningful leverage gives Amgen a different financial profile from a narrowly focused drug developer.

Peer set — price, market value and MoonshotScore
CompanyPriceMarket valueScore
Eli Lilly and Company (LLY) Same industry, near in market value$1382.75 Nov 18, 2026$1.23T98 5-pillar Nov 18, 2026
Sanofi (SNY) Same industry, near in market value$47.12 Nov 18, 2026$113B87 5-pillar Nov 18, 2026
AstraZeneca PLC (AZN) Same industry, near in market value$178.76 Nov 18, 2026$277B85 5-pillar Nov 18, 2026
Bristol-Myers Squibb Company (BMY) Same industry, near in market value$59.56 Nov 18, 2026$122B85 5-pillar Nov 18, 2026
Amgen (AMGN) — this page$443.89$240B84
AbbVie Inc. (ABBV) Same industry, near in market value$286.01 Nov 18, 2026$506B83 5-pillar Nov 18, 2026
Johnson & Johnson (JNJ) Same industry, near in market value$272.70 Nov 18, 2026$656B83 5-pillar Nov 18, 2026
Novartis AG (NVS) Named competitor$155.21 Nov 18, 2026$293B82 5-pillar Nov 18, 2026
GSK plc (GSK) Same industry, near in market value$48.58 Nov 18, 2026$97.4B77 5-pillar Nov 18, 2026
Gilead Sciences, Inc. (GILD) Named competitor$168.98 Nov 18, 2026$210B72 5-pillar Nov 18, 2026
Merck & Co., Inc. (MRK) Named competitor$137.78 Nov 18, 2026$340B69 5-pillar Nov 18, 2026
Pfizer Inc. (PFE) Named competitor$28.06 Nov 18, 2026$160B67 5-pillar Nov 18, 2026
Grifols, S.A. (GRFS) Same industry, near in market value$8.47 Nov 18, 2026$5.76B60 5-pillar Nov 18, 2026

Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.

Screen more Healthcare stocks

The records behind this page

Analyst targets & estimates

What analysts have on file

Price target, low to high
$230.00 – $531.00
Consensus target
$426.29
Median target
$430.00

Consensus record · Captured .

Measured against a quoted price of $443.89 (as of Nov 18, 2026).

Insider activity

Form 4 records via FMP · Of the newest 500 records, those within the last 180 days, newest dated Nov 6, 2026

Transactions
22
Identified insiders
8
Purchases
0
Sales
4
Other transactions
18

Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.

Who holds the shares?

Institutional ownership reported through 13F filings.

Tracked investors

Which of the 16 named investors we follow held AMGN in their latest 13F filing, and what they did against the filing before it.

InvestorManager13F quarterPortfolio weightValueLast quarter
Bridgewater AssociatesFounded by Ray DalioQ3 20260.21%$48.33MAdded +424.3% shares

See all tracked investor portfolios

How to read these figures

These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.

What has been published about Amgen (AMGN)?

Read these with our analysis →

What Investors Ask About Amgen (AMGN) — Healthcare

The last 2 questions are answered from this page's own dated data, not from the research.

How does Amgen make money from Prolia and Repatha?

Amgen manufactures and sells these prescription medicines into healthcare channels serving prescribers and patients; treatment demand and prescribing activity feed product revenue through wholesalers and direct channels.

Why is Amgen building MariTide manufacturing capacity before launch?

Management is investing ahead of launch to prepare manufacturing capacity for expected volume growth, making capital spending and cash conversion important evidence of execution.

Can Amgen fund the MariTide build while carrying heavy debt?

Current operating cash generation covers recent capital spending comfortably, but debt substantially exceeds cash and short-term investments. Continued product cash flow is therefore central to funding capacity expansion without further constraining financial flexibility.

Why does Amgen’s product mix matter beyond Enbrel?

Amgen earns revenue across medicines including Prolia, Repatha and Otezla, while its broader portfolio reaches inflammation, bone health, cardiovascular disease, cancer care and other specialties. The business is consequently exposed to demand across a portfolio rather than Enbrel alone.

What is the AMGN stock price today?

The last price recorded for Amgen Inc. (AMGN), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.

What is the AMGN price target?

The analyst consensus price target for Amgen Inc. (AMGN), with its range and the date it was captured from FMP, is listed under Analyst targets & estimates on this page. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.

Research written by Codex (gpt-5.6-sol) on 2026-09-12. AI-authored analysis; source dates are listed under Sources. Reviewed by Sedat ANAK, Founder and Editor-in-Chief, on 2026-11-07.

Sources: the source register lists the 42 figures on this page — 1 from SEC filings and earnings calls, 35 from Financial Modeling Prep (FMP), 3 with no recorded source, 2 computed by us, formula shown in the register and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.

Publication details and research sources
Published
Research standards
Methodology · Editorial policy · Corrections

Sources (as of 2026-09-12), by section of the research

  • Summary at the top of the page: Business description; Revenue by segment; Quarterly income statement (USD thousands); Operating cash flow by quarter (USD millions); Cash, investments and debt; Management outlook — dated call excerpts
  • 1. What is Amgen (AMGN), and what does it report?: Business description; Sector / industry (provider taxonomy); Revenue by segment; Quarterly income statement (USD thousands); Annual revenue and net result (USD millions)
  • 2. What do the latest results show for Amgen (AMGN)?: Quarterly income statement (USD thousands); Reported versus estimated, last 8 quarters; Operating cash flow by quarter (USD millions); Management outlook — dated call excerpts; Annual revenue and net result (USD millions)
  • 3. What are the financial strengths and risks for Amgen (AMGN)?: Trailing twelve-month ratio set; Operating cash flow by quarter (USD millions); Cash, investments and debt; Cash and investment components; Cash and short-term investments over time (USD millions); Cash against market value; Annual revenue and net result (USD millions); Distress and quality screens; Management outlook — dated call excerpts
  • 4. What should you watch next at Amgen (AMGN)?: Management outlook — dated call excerpts; Operating cash flow by quarter (USD millions); Quarterly income statement (USD thousands); Reported versus estimated, last 8 quarters; Next earnings report; Analyst revenue and earnings estimates (average); Most recent periodic reports
  • 5. How does Amgen compare with its peers?: Business description; Revenue by segment; Annual revenue and net result (USD millions); Quarterly income statement (USD thousands); Operating cash flow by quarter (USD millions); Cash, investments and debt; Management outlook — dated call excerpts
  • FAQ: How does Amgen make money from Prolia and Repatha?: Business description; Revenue by segment
  • FAQ: Why is Amgen building MariTide manufacturing capacity before launch?: Management outlook — dated call excerpts; Operating cash flow by quarter (USD millions)
  • FAQ: Can Amgen fund the MariTide build while carrying heavy debt?: Operating cash flow by quarter (USD millions); Cash, investments and debt; Cash and short-term investments over time (USD millions); Cash against market value; Management outlook — dated call excerpts
  • FAQ: Why does Amgen’s product mix matter beyond Enbrel?: Business description; Revenue by segment
Data Sources & Methodology
Figures come from Financial Modeling Prep (FMP). If FMP has no figure for a ticker, a price or fundamental may come from a Yahoo Finance fallback, or a price from an Alpaca fallback. SEC EDGAR is used only for filing links and company identity details (legal name, address), never for figures. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.

ETFs that hold AMGN

Funds in our ETF coverage that list AMGN among the top 10 holdings on their fund page, largest weight first. Each weight is the fund's reported holding weight as of the date in its row.

ETFWeightHoldings as of
DVGR ETF4.72%
PBPH ETF4.56%
State Street SPDR Dow Jones Industrial Average ETF Trust (DIA)4.43%
Eventide High Dividend ETF (ELCV)4.41%
iShares Evolved U.S. Innovative Healthcare ETF (IEIH)4.38%
Simplify Health Care ETF (PINK)3.88%
VHT ETF2.80%
ProShares - Ultra Health Care (RXL)2.56%
Tidal Trust III - Fundstrat Granny Shots US Large Cap ETF (GRNY)2.55%
IXJ ETF2.52%